eligibility_summary
Age ≥18 with metastatic castration‑resistant prostate adenocarcinoma, measurable disease or bone‑only with PSA≥1, progressed, prior ≥2 lines incl ≥1 ARSI and eligible targeted therapy, castrate testosterone, ECOG 0–1, adequate renal/hepatic/pulmonary/cardiac, ANC>1500, Hgb>9, Plt>100k, contraception, palliative RT allowed except within 2 wks pre‑leukapheresis. Exclude: active autoimmune on immunosuppression, steroids>15 mg/d, other investigational drugs, uncontrolled infection/illness, untreated brain mets, ongoing irAE tx, major neuro disease, allergies.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2 trial in mCRPC testing: 1) STEAP1 CAR T cells (autologous, gene-engineered cellular immunotherapy). Mechanism: patient T cells are modified to express a chimeric antigen receptor that binds STEAP1 on prostate cancer cells, activating T-cell cytotoxicity and cytokine signaling to kill STEAP1+ tumor cells. 2) Enzalutamide (oral small‑molecule androgen receptor inhibitor). Mechanism: blocks AR signaling, suppressing androgen-driven transcription and tumor growth, may augment CAR T activity. Lymphodepletion with cyclophosphamide (DNA‑alkylating chemotherapy) and fludarabine (purine analog antimetabolite) reduces host lymphocytes to enhance CAR T engraftment/expansion. Targets/pathways: STEAP1-expressing prostate tumor cells, androgen receptor pathway, conditioning targets peripheral lymphocytes.